Recombinant Anti-ErbB2 / HER2 antibody [SP101] (ab231438)

Multiplex immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human triple-positive breast carcinoma tissue sections labeling ErbB2 / HER2 with ab231438 at 1/100 dilution (1.59 µg/ml). Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins and Opal Polymer HRP Ms + Rb was used as the secondary antibody. DAPI was used as the nuclear counterstain.

Panel A: merged staining of anti-Progesterone Receptor (PR) (magenta; Opal™690), anti-HER2 (red; Opal™570) and anti-Estrogen Receptor (ER) (green; Opal™520) on human triple-positive breast carcinoma.
Panel B: anti-PR stained on nucleus of cancer cells.
Panel C: anti-HER2 stained on membrane of cancer cells.
Panel D: anti-ER stained on nucleus of cancer cells.

The section was incubated in three rounds of staining: in the order of ab16661 for 30 mins, then ab16660 and ab231438 for 10 mins at room temperature. Each round was followed by a separate fluorescent tyramide signal amplification system.

The immunostaining was performed on a Leica Biosystems BOND® RX instrument with an Opal™ 4-color kit. Image acquisition was performed with Leica SP8 confocal microscope.

Blocking/Diluting Buffer and concentration: 5% NFDM /TBST

Multiplex immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human mammary gland tissue sections labeling ErbB2 / HER2 with ab231438 at 1/100 dilution (1.59 µg/ml). Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins and Opal Polymer HRP Ms + Rb was used as the secondary antibody. DAPI was used as the nuclear counterstain.

Panel A: merged staining of anti-Progesterone Receptor (PR) (magenta; Opal™690), anti-HER2 (red; Opal™570) and anti-Estrogen Receptor (ER) (green; Opal™520) on human mammary gland.
Panel B: anti-PR stained on nucleus of some ductal cells.
Panel C: anti-HER2 stained on no cells.
Panel D: anti-ER stained on nucleus of some ductal cells.

The section was incubated in three rounds of staining: in the order of ab16661 for 30 mins, then ab16660 and ab231438 for 10 mins at room temperature. Each round was followed by a separate fluorescent tyramide signal amplification system.

The immunostaining was performed on a Leica Biosystems BOND® RX instrument with an Opal™ 4-color kit. Image acquisition was performed with Leica SP8 confocal microscope.

Panel A: merged staining of anti-Progesterone Receptor (PR) (magenta; Opal™690), anti-HER2 (red; Opal™570) and anti-Estrogen Receptor (ER) (green; Opal™520) on human triple-negative breast carcinoma.
Panel B: anti-PR stained on no cells.
Panel C: anti-HER2 stained on no cells.
Panel D: anti-ER stained on no cells.

The section was incubated in three rounds of staining: in the order of ab16661 for 30 mins, then ab16660 and ab231438 for 10 mins at room temperature. Each round was followed by a separate fluorescent tyramide signal amplification system.

The immunostaining was performed on a Leica Biosystems BOND® RX instrument with an Opal™ 4-color kit. Image acquisition was performed with Leica SP8 confocal microscope.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human breast carcinoma tissue sections labeling ErbB2 / HER2 with ab231438 at 1/100 dilution (6.38 µg/ml). Heat mediated antigen retrieval with Bond™ Epitope Retrieval Solution 1 (pH 6.0) for 10mins Goat Anti-Rabbit & Mouse IgG (HRP) was used as the secondary antibody. Hematoxylin was used as a counterstain. Membranous staining on the human breast carcinoma, performed on a Leica Biosystems BOND™ RX instrument.
The section was incubated with ab231438 for 30 mins at room temperature.

Formalin-fixed, paraffin-embedded human breast carcinoma tissue stained for ErbB2 / HER2 using ab231438 at 1/100 dilution in immunohistochemical analysis.